Online Livestream
West Coast
2nd Medical Affairs & Rare DiseaseWest Coast
Event Overview

The new coronavirus has paralyzed our world, but older diseases remain as dangerous as ever.  Rare disease patient needs have become even more challenging in an age of social distancing and fears of contagion.

To help serve the patients who are under the most risk and are least able to wait for society to reopen, Dynamic Global Events invites you to participate in the 2nd annual Medical Affairs & Rare Disease – West Coast conference – this year held entirely streaming online.  At a time when people are forced to stay apart, this forum helps you unite multi-stakeholder teams across functions, organizations, and therapeutic areas, in order to solve problems and identify rare disease solutions.

Conference
New Topics
Featured Speakers
Andy Overmyer
Akcea Therapeutics
Head of Global Business Operations
Angela Ramirez Holmes
Cal Rare
Founder/President
Barbara Wuebbels
PROFESSIONAL PATIENT ADVOCATES IN LIFE SCIENCE
Chairman
Christine Von Raesfeld
PEOPLE WITH EMPATHY
Founder / CEO
Colin Scott
HIGHLAND AIRS CONSULTING
Managing Partner
Dan Donovan
rareLife solutions
Co-Founder & CEO
Harsha K. Rajasimha
Founder Chairman, Indo US Organization for Rare Diseases
Founder and Chairman, INDOUSRARE
Jim Murray
PEOPLE WITH EMPATHY
Board Member
Joan A. Chambers
The Center for Information & Study on Clinical Research Participation (CISCRP)
Senior Director, Marketing & Outreach
Jon Kaskey
WITHIN3
Senior Director of Business Partnerships
Maureen McArthur Hart
Global Genes
Director, Research
May Orfali
BIOASIS TECHNOLOGIES
Chief Medical Officer
Michael Forstner
PrimeVigilance
Senior Vice President and Head of Pharmacoepidemiology and Risk Management
Natalie Douglas
Co-Founder, RAREITI
Vice Chairman, GLOBAL GENES
Oscar Segurado
ASC Therapeutics
Chief Medical Officer
Robert Consalvo
H1 INSIGHTS
Director of Strategic Commercial Engagement
Sarah Krug
HEALTH COLLABORATORY; CANCER 101
Founder; CEO
Sheila Bose
SB Lifesciences Consulting, Inc
President
Spandan Chakrabarti
PEOPLE WITH EMPATHY
Co-Founder/CFO
Steven G. Rizk
Rype Health
Senior Director Medical Strategy
Tom Lester
Audentes Therapeutics
Former Executive Director Program Management
Vij Senthilnathan
PEOPLE WITH EMPATHY
Board Member
Wendy White
Co-Founder, RAREITI
Chairman, GLOBAL GENES
Event Schedule

The lack of published literature in rare disease presents an impediment to progressing disease understanding and advancing therapies. Companies developing medical publishing programs need to consider that this is not your everyday medical publications program for a more common disease. As an example, to have a more tangible impact, rare disease publications must be open access and freely available to all stakeholders in rare, including the patient. Breaking down the process we will:

  • Discuss the best methods, timelines, and content requirements for rare disease publications
  • Highlight crucial differences between publishing for rare diseases and more common types
  • Encourage that rare disease clinical trial results are shared with the patient community as a priority and in a legally compliant manner

The patient voice must move to the forefront of clinical trial planning, or else you are at risk of missed endpoints, low enrollment, and wasted time and money.  Dedicated MSL teams can be powerful tools for gathering patient information and, in turn, properly structuring your trials.  With their direct access to the patient voice, they are also vital in educating clinical staff about the disease. 

  • Reorient logistics, consent forms, and follow-ups around the patient voice
  • Rely on medical affairs professionals to verify your assumptions about age spread and disease severity
  • Strengthen advisory board meetings through medical affairs input

Commercial, medical affairs, and medical communications teams must be closely involved from the earliest stages in order to accurately guide sales. This is especially true for rare disease therapeutics for which doctors might see only one patient per month at the most. The entire clinical and medical affairs management cycles for rare disease will have to significantly change in response to the COVID-19 pandemic.

  • Pinpoint the medical affairs and communication partnerships and messaging most essential in new APDS therapeutics
  • Track the key steps in expanding rare disease therapeutics for a new pediatric indication
  • Adapt your methods and messaging to a post-coronavirus world
  • Create trust among stakeholders
  • Envision innovative partnerships focused on solutions, not profits
  • Prioritize transparency, accountability, and conflict resolution in partnerships
  • Grasp how small investments can lead to big returns
  • Create trust among stakeholders
  • Envision innovative partnerships focused on solutions, not profits
  • Prioritize transparency, accountability, and conflict resolution in partnerships
  • Grasp how small investments can lead to big returns
  • Actionable Implications to Achieve Clinical Development, Product Launch Goals,
    Drug Safety and Favorable Outcomes
  • Building High-performing Multi-stakeholder Teams
  • Leading Internal Project Teams Across Functions, Geographies and Therapeutic
    Areas
  • Collaborating Across Organizations -- Science, Business and Non-profits
Register Now

This window is secured by 256 bit encryption on a PCI compliant network. Click here to view this window in its own page.

Subscribe to Conference Updates
Join our e-newsletter list to follow closely all news.
Event Sponsors
15
Speakers
21
Days
251
Participants
125
Workshops
90
Venue
Contact Us